These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26478531)

  • 1. Conversion to Belatacept based regimen does not change T-cell phenotype and function in renal transplantation.
    Matz M; Fabritius K; Liu J; Lorkowski C; Brakemeier S; Unterwalder N; Dürr M; Mashreghi MF; Neumayer HH; Budde K
    Transpl Immunol; 2015 Nov; 33(3):176-84. PubMed ID: 26478531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching renal transplant recipients to belatacept therapy: results of a real-life gradual conversion protocol.
    Malvezzi P; Fischman C; Rigault G; Jacob MC; Raskovalova T; Jouve T; Janbon B; Rostaing L; Cravedi P
    Transpl Immunol; 2019 Oct; 56():101207. PubMed ID: 31071442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive minimization with mTOR inhibitors and belatacept.
    Diekmann F
    Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28- Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection.
    Castro-Rojas CM; Godarova A; Shi T; Hummel SA; Shields A; Tremblay S; Alloway RR; Jordan MB; Woodle ES; Hildeman DA
    Transplantation; 2020 May; 104(5):1058-1069. PubMed ID: 31415033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-Regulation of Surface CD28 under Belatacept Treatment: An Escape Mechanism for Antigen-Reactive T-Cells.
    de Graav GN; Hesselink DA; Dieterich M; Kraaijeveld R; Weimar W; Baan CC
    PLoS One; 2016; 11(2):e0148604. PubMed ID: 26919152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.
    Choi M; Bachmann F; Wu K; Lachmann N; Schmidt D; Brakemeier S; Duerr M; Kahl A; Eckardt KU; Budde K; Nickel P
    BMC Nephrol; 2020 Aug; 21(1):354. PubMed ID: 32819287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costimulatory Blockade and Use of mTOR Inhibitors: Avoiding Injury Part 2.
    Wojciechowski D; Vincenti F
    Adv Chronic Kidney Dis; 2016 Sep; 23(5):306-311. PubMed ID: 27742385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients.
    Xu H; Samy KP; Guasch A; Mead SI; Ghali A; Mehta A; Stempora L; Kirk AD
    Am J Transplant; 2016 Feb; 16(2):550-64. PubMed ID: 26436448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with belatacept rescue therapy in kidney transplant recipients.
    Brakemeier S; Kannenkeril D; Dürr M; Braun T; Bachmann F; Schmidt D; Wiesener M; Budde K
    Transpl Int; 2016 Nov; 29(11):1184-1195. PubMed ID: 27514317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of Belatacept on virus-specific memory versus de novo allo-specific T cell responses of kidney transplant recipients and healthy donors.
    Kühne JF; Neudörfl C; Beushausen K; Keil J; Malysheva S; Wandrer F; Haller H; Messerle M; Blume C; Neuenhahn M; Schlott F; Hammerschmidt W; Zeidler R; Falk CS
    Transpl Immunol; 2020 Aug; 61():101291. PubMed ID: 32330566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different in vitro proliferation and cytokine-production inhibition of memory T-cell subsets after calcineurin and mammalian target of rapamycin inhibitors treatment.
    Merino D; San Segundo D; Medina JM; Rodrigo E; Asensio E; Irure J; Fernández-Fresnedo G; Arias MA; López-Hoyos M
    Immunology; 2016 Jun; 148(2):206-15. PubMed ID: 26931075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costimulatory blockade with mTor inhibition abrogates effector T-cell responses allowing regulatory T-cell survival in renal transplantation.
    Bestard O; Cassis L; Cruzado JM; Torras J; Franquesa M; Gil-Vernet S; Lucia M; Grinyó JM
    Transpl Int; 2011 May; 24(5):451-60. PubMed ID: 21294788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-inhibitory profile and cytotoxicity of CD57
    Kraaijeveld R; de Graav GN; Dieterich M; Litjens NHR; Hesselink DA; Baan CC
    Clin Exp Immunol; 2018 Mar; 191(3):363-372. PubMed ID: 29027667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Belatacept prophylaxis against organ rejection in adult kidney-transplant recipients.
    Del Bello A; Marion O; Milongo D; Rostaing L; Kamar N
    Expert Rev Clin Pharmacol; 2016; 9(2):215-27. PubMed ID: 26691282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion from calcineurin inhibitors to belatacept-based immunosuppressive therapy skews terminal proliferation of non-classical monocytes and lowers lymphocyte counts.
    Bredewold OW; van Oeveren-Rietdijk AM; Florijn B; Rotmans JI; de Fijter JW; van Kooten C; van Zonneveld AJ; de Boer HC
    Transpl Immunol; 2024 Feb; 82():101976. PubMed ID: 38199271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased frequency of peripheral CD4(+) CD161(+) Th(17) -precursor cells in kidney transplant recipients on long-term therapy with Belatacept.
    Vondran FW; Timrott K; Kollrich S; Klempnauer J; Schwinzer R; Becker T
    Transpl Int; 2012 Apr; 25(4):455-63. PubMed ID: 22348376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alloreactive CD154-expressing T-cell subsets with differential sensitivity to the immunosuppressant, belatacept: potential targets of novel belatacept-based regimens.
    Ashokkumar C; Ganguly B; Townsend R; White J; Levy S; Moritz M; Mazariegos G; Sun Q; Sindhi R
    Sci Rep; 2015 Oct; 5():15218. PubMed ID: 26472085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TIGIT regulates apoptosis of risky memory T cell subsets implicated in belatacept-resistant rejection.
    Sun H; Hartigan CR; Chen CW; Sun Y; Tariq M; Robertson JM; Krummey SM; Mehta AK; Ford ML
    Am J Transplant; 2021 Oct; 21(10):3256-3267. PubMed ID: 33756063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early conversion to belatacept after renal transplantation.
    Nair V; Liriano-Ward L; Kent R; Huprikar S; Rana M; Florman SS; Delaney VB; Menon MC; Sehgal V; Miko L; Khaim R; Benvenisty A; Lerner S; Arvelakis A; Wadhera V; Ames S; Shapiro R
    Clin Transplant; 2017 May; 31(5):. PubMed ID: 28267882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion to belatacept after lung transplantation: Report of 10 cases.
    Brugière O; Vallée A; Raimbourg Q; Peraldi MN; de Verdière SC; Beaumont L; Hamid A; Zrounba M; Roux A; Picard C; Parquin F; Glorion M; Oniszczuk J; Hertig A; Mal H; Bunel V
    PLoS One; 2023; 18(3):e0281492. PubMed ID: 36920935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.